Does the media prefer ETON or BIOA?

In the previous week, BioAge Labs had 15 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for BioAge Labs and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.20 beat BioAge Labs' score of 0.55 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AVLN or BIOA?

In the previous week, BioAge Labs had 9 more articles in the media than Avalyn Pharma. MarketBeat recorded 17 mentions for BioAge Labs and 8 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.80 beat BioAge Labs' score of 0.55 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANIP or BIOA?

In the previous week, BioAge Labs had 11 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 17 mentions for BioAge Labs and 6 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.64 beat BioAge Labs' score of 0.55 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIOA or LBRX?

In the previous week, BioAge Labs had 13 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 17 mentions for BioAge Labs and 4 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.01 beat BioAge Labs' score of 0.55 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XERS or BIOA?

In the previous week, BioAge Labs had 10 more articles in the media than Xeris Biopharma. MarketBeat recorded 17 mentions for BioAge Labs and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.86 beat BioAge Labs' score of 0.55 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioAge Labs (BIOA) Competitors

$8.49 -0.16 (-1.85%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.48 -0.01 (-0.12%)

As of 09/11/2026 07:30 PM Eastern

Compare

BIOA vs. ETON, AVLN, ANIP, LBRX, and XERS

Should you buy BioAge Labs stock or one of its competitors? BioAge Labs's main competitors and comparable companies include Eton Pharmaceuticals (ETON), Avalyn Pharma (AVLN), ANI Pharmaceuticals (ANIP), LB Pharmaceuticals (LBRX), and Xeris Biopharma (XERS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BioAge Labs compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Eton Pharmaceuticals has a net margin of 12.02% compared to BioAge Labs' net margin of -912.26%. Eton Pharmaceuticals' return on equity of 40.13% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
BioAge Labs	-912.26%	-28.99%	-27.09%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 17.6% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eton Pharmaceuticals currently has a consensus price target of $67.50, suggesting a potential upside of 18.26%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 330.76%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, BioAge Labs had 15 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for BioAge Labs and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.20 beat BioAge Labs' score of 0.55 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	20.40	-$4.60M	$0.38	150.21
BioAge Labs	$8.99M	43.35	-$80.61M	-$2.38	N/A

Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Avalyn Pharma currently has a consensus price target of $60.00, suggesting a potential upside of 78.73%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 330.76%. Given BioAge Labs' higher probable upside, analysts clearly believe BioAge Labs is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Avalyn Pharma has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
BioAge Labs	$8.99M	43.35	-$80.61M	-$2.38	N/A

In the previous week, BioAge Labs had 9 more articles in the media than Avalyn Pharma. MarketBeat recorded 17 mentions for BioAge Labs and 8 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.80 beat BioAge Labs' score of 0.55 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. Avalyn Pharma's return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
BioAge Labs	-912.26%	-28.99%	-27.09%

Summary

Avalyn Pharma beats BioAge Labs on 7 of the 12 factors compared between the two stocks.

How does BioAge Labs compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

ANI Pharmaceuticals has a net margin of 11.07% compared to BioAge Labs' net margin of -912.26%. ANI Pharmaceuticals' return on equity of 27.37% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
BioAge Labs	-912.26%	-28.99%	-27.09%

In the previous week, BioAge Labs had 11 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 17 mentions for BioAge Labs and 6 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.64 beat BioAge Labs' score of 0.55 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$978.38M	1.65	$78.34M	$4.64	15.13
BioAge Labs	$8.99M	43.35	-$80.61M	-$2.38	N/A

ANI Pharmaceuticals presently has a consensus target price of $105.57, indicating a potential upside of 50.41%. BioAge Labs has a consensus target price of $36.57, indicating a potential upside of 330.76%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

ANI Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ANI Pharmaceuticals beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to LB Pharmaceuticals?

BioAge Labs (NASDAQ:BIOA) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

BioAge Labs presently has a consensus target price of $36.57, indicating a potential upside of 330.76%. LB Pharmaceuticals has a consensus target price of $49.63, indicating a potential upside of 11.19%. Given BioAge Labs' higher probable upside, analysts clearly believe BioAge Labs is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, BioAge Labs had 13 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 17 mentions for BioAge Labs and 4 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.01 beat BioAge Labs' score of 0.55 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. LB Pharmaceuticals' return on equity of -25.92% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

LB Pharmaceuticals has lower revenue, but higher earnings than BioAge Labs. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	43.35	-$80.61M	-$2.38	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Summary

LB Pharmaceuticals beats BioAge Labs on 8 of the 13 factors compared between the two stocks.

How does BioAge Labs compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

In the previous week, BioAge Labs had 10 more articles in the media than Xeris Biopharma. MarketBeat recorded 17 mentions for BioAge Labs and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.86 beat BioAge Labs' score of 0.55 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of -5.12% compared to BioAge Labs' net margin of -912.26%. Xeris Biopharma's return on equity of 338.21% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
BioAge Labs	-912.26%	-28.99%	-27.09%

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 17.6% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than BioAge Labs. Xeris Biopharma is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A
BioAge Labs	$8.99M	43.35	-$80.61M	-$2.38	N/A

Xeris Biopharma has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Xeris Biopharma presently has a consensus price target of $12.80, suggesting a potential upside of 71.81%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 330.76%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Xeris Biopharma and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$397.01M	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-3.57	799.75	275.24	25.29
Price / Sales	43.35	763.36	655.99	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	1.12	10.39	10.33	6.20
Net Income	-$80.61M	$2.85B	$3.50B	$358.50M
7 Day Performance	-11.47%	-3.61%	-3.32%	-2.35%
1 Month Performance	-18.99%	0.86%	-0.41%	-2.77%
1 Year Performance	76.88%	3.47%	19.21%	7.63%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOA BioAge Labs	2.5769 of 5 stars	$8.49 -1.8%	$36.57 +330.8%	+72.9%	$397.01M	$8.99M	N/A	N/A	Analyst Forecast
ETON Eton Pharmaceuticals	4.4103 of 5 stars	$58.45 flat	$67.50 +15.5%	+224.9%	$1.67B	$79.95M	153.82	20	Positive News
AVLN Avalyn Pharma	3.5597 of 5 stars	$37.39 flat	$60.00 +60.5%	N/A	$1.66B	N/A	N/A	51	News Coverage Positive News Analyst Upgrade Gap Down
ANIP ANI Pharmaceuticals	3.8739 of 5 stars	$71.23 flat	$105.83 +48.6%	-28.9%	$1.64B	$883.37M	15.35	600	Analyst Forecast
LBRX LB Pharmaceuticals	1.7431 of 5 stars	$49.34 flat	$49.63 +0.6%	N/A	$1.59B	N/A	N/A	16	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. ETON, AVLN, ANIP, LBRX, and XERS

How does BioAge Labs compare to Eton Pharmaceuticals?

Summary

How does BioAge Labs compare to Avalyn Pharma?

Summary

How does BioAge Labs compare to ANI Pharmaceuticals?

Summary

How does BioAge Labs compare to LB Pharmaceuticals?

Summary

How does BioAge Labs compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. ETON, AVLN, ANIP, LBRX, and XERS

How does BioAge Labs compare to Eton Pharmaceuticals?

Is ETON or BIOA more profitable?

Do insiders and institutionals have more ownership in ETON or BIOA?

Do analysts rate ETON or BIOA?

Does the media prefer ETON or BIOA?

Which has stronger valuation and earnings, ETON or BIOA?

Which has more risk & volatility, ETON or BIOA?

Summary

How does BioAge Labs compare to Avalyn Pharma?

Do analysts rate AVLN or BIOA?

Which has stronger earnings and valuation, AVLN or BIOA?

Does the media favor AVLN or BIOA?

Is AVLN or BIOA more profitable?

Summary

How does BioAge Labs compare to ANI Pharmaceuticals?

Is ANIP or BIOA more profitable?

Does the media favor ANIP or BIOA?

Which has higher earnings and valuation, ANIP or BIOA?

Do analysts rate ANIP or BIOA?

Which has more risk & volatility, ANIP or BIOA?

Do institutionals and insiders believe in ANIP or BIOA?

Summary

How does BioAge Labs compare to LB Pharmaceuticals?

Do analysts recommend BIOA or LBRX?

Does the media favor BIOA or LBRX?

Is BIOA or LBRX more profitable?

Which has better earnings and valuation, BIOA or LBRX?

Summary

How does BioAge Labs compare to Xeris Biopharma?

Does the media favor XERS or BIOA?

Is XERS or BIOA more profitable?

Do institutionals & insiders hold more shares of XERS or BIOA?

Which has better earnings and valuation, XERS or BIOA?

Which has more risk and volatility, XERS or BIOA?

Do analysts rate XERS or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools